Kamada (XTAE:KMDA) Cyclically Adjusted Revenue per Share: ₪10.24 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTAE:KMDA Kamada Ltd XTAE:KMDA
87 GF Score
Price ₪24.91
GF Value ₪25.86
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Kamada Cyclically Adjusted Revenue per Share?

Kamada XTAE:KMDA 87 Cyclically Adjusted Revenue per Share is ₪10.24 as of Jun. 2026. GuruFocus rates XTAE:KMDA with a GF Score™ of 87/100 and a GF Value™ of ₪25.86 (Fairly Valued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Kamada's adjusted revenue per share for the three months ended in Jun. 2026 was ₪2.863. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₪10.24 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Kamada's average Cyclically Adjusted Revenue Growth Rate was 5.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Kamada was 4.40% per year. The lowest was 4.00% per year. And the median was 4.20% per year.

As of today (2026-09-08), Kamada's current stock price is ₪24.91. Kamada's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₪10.24. Kamada's Cyclically Adjusted PS Ratio of today is 2.43.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kamada was 3.05. The lowest was 1.57. And the median was 2.24.


Kamada  (XTAE:KMDA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Kamada's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=24.91/10.24
=2.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kamada was 3.05. The lowest was 1.57. And the median was 2.24.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Kamada Cyclically Adjusted Revenue per Share Related Terms


Kamada Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Kamada's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kamada Cyclically Adjusted Revenue per Share Chart

Kamada Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.22 8.69 9.06 9.36 9.78

Kamada Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.74 9.86 9.78 10.04 10.24

XTAE:KMDA vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kamada's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kamada Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kamada's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kamada's Cyclically Adjusted PS Ratio falls into.


XTAE:KMDA
87GF Score
Kamada Ltd XTAE:KMDA
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kamada Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kamada's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.863/333.9520*333.9520
=2.863

Current CPI (Jun. 2026) = 333.9520.

Kamada Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.685 241.428 2.331
201612 1.824 241.432 2.523
201703 0.972 243.801 1.331
201706 2.626 244.955 3.580
201709 1.718 246.819 2.324
201712 1.965 246.524 2.662
201803 1.257 249.554 1.682
201806 2.514 251.989 3.332
201809 1.134 252.439 1.500
201812 3.863 251.233 5.135
201903 1.971 254.202 2.589
201906 2.597 256.143 3.386
201909 2.399 256.759 3.120
201912 2.321 256.974 3.016
202003 2.310 258.115 2.989
202006 2.887 257.797 3.740
202009 2.339 260.280 3.001
202012 2.096 260.474 2.687
202103 1.678 264.877 2.116
202106 1.561 271.696 1.919
202109 1.645 274.310 2.003
202112 2.335 278.802 2.797
202203 1.855 287.504 2.155
202206 1.634 296.311 1.842
202209 2.009 296.808 2.260
202212 2.868 296.797 3.227
202303 2.049 301.836 2.267
202306 2.494 305.109 2.730
202309 2.131 307.789 2.312
202312 1.926 306.746 2.097
202403 1.926 312.332 2.059
202406 2.316 314.175 2.462
202409 2.282 315.301 2.417
202412 1.907 315.605 2.018
202503 2.345 319.799 2.449
202506 2.380 322.561 2.464
202509 2.411 324.800 2.479
202512 2.330 324.054 2.401
202603 2.313 330.213 2.339
202606 2.863 333.952 2.863

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₪10.24 mean?
Kamada (XTAE:KMDA) has a Cyclically Adjusted Revenue per Share of ₪10.24 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kamada and its competitors.
Is Kamada's Cyclically Adjusted Revenue per Share too high?
Kamada's current Cyclically Adjusted Revenue per Share is ₪10.24. Overall, Kamada has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kamada's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Kamada's Cyclically Adjusted Revenue per Share of ₪10.24 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kamada and its competitors. Kamada's current Cyclically Adjusted Revenue per Share is ₪10.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kamada stock overvalued right now?
Based on GuruFocus' analysis, Kamada (XTAE:KMDA) is currently considered Fairly Valued. The stock's GF Value™ is ₪25.86, compared to a current price of ₪24.91 — trading 3.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₪10.24. Kamada's overall GF Score™ is 87/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Kamada (XTAE:KMDA), the current Cyclically Adjusted Revenue per Share is ₪10.24 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kamada (XTAE:KMDA) Overvalued in 2026?

Based on GuruFocus' analysis, Kamada stock appears to be undervalued. The current stock price of ₪24.91 is trading 3.7% below its estimated GF Value™ of ₪25.86. GuruFocus considers Kamada to be Fairly Valued.

Key valuation signals for XTAE:KMDA:

  • Cyclically Adjusted Revenue per Share: ₪10.24
  • GF Value™: ₪25.86 vs. price of ₪24.91 (3.7% below fair value)
  • GF Score™: 87/100 with 1 warning sign

No single metric tells the full story. See the XTAE:KMDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kamada Business Description

Other Exchanges KMDA:USA
Address 2 Holzman Street, P.O. Box 4081, Science Park, Rehovot, ISR, 7670402
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
87GF Score

Get the complete analysis for XTAE:KMDA

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪24.91
Price
₪25.86
GF Value